Literature DB >> 10459850

Discordant expression of insulin-like growth factors and their receptor messenger ribonucleic acids in endometrial carcinomas relative to normal endometrium.

R N Roy1, A H Gerulath, A Cecutti, B R Bhavnani.   

Abstract

The inappropriate expressions of insulin-like growth factors (IGF-I and II) and IGF-I receptor (IGF-IR) are implicated in the malignant growth of many cancers. To determine changes, if any, in the levels of expression of IGFs and IGF receptor genes in neoplastic endometrium, relative to normal endometrium, the mRNA levels of IGF-I and II and of IGF-IR and IIR were measured in samples of endometrial carcinomas (EC) and normal endometrium, through all phases of the menstrual cycle, by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) assays. In normal endometrium, the mRNA levels of IGF-I were elevated in the proliferative and early secretory phases. The IGF-II mRNAs were relatively high in the proliferative phase, but unaltered through early and late secretory phases. Significantly elevated levels of IGF-II transcripts were observed during the menstrual phase, suggesting a possible role of IGF-II in endometrial regeneration. A positive correlation between the levels of IGF-I and IGF-IR mRNAs, apparent in the samples of normal endometrium, was not observed in endometrial carcinomas. The IGF-IR and IIR mRNA levels were elevated in endometrial carcinoma samples. On the other hand, the IGF-I and II mRNA levels were conspicuously low in many carcinoma samples, which were not associated with hyperplasia (type II EC), but relatively elevated in two other carcinoma samples, associated with adenomatous hyperplasia (type I EC). These results albeit with few samples suggest the possibility that the overexpressed receptor, IGF-IR, could be activated differently in two types of endometrial carcinomas, namely ligand-dependently in type I ECs and ligand-independently in type II ECs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10459850     DOI: 10.1016/s0303-7207(99)00092-1

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  7 in total

1.  Common genetic variation within IGFI, IGFII, IGFBP-1, and IGFBP-3 and endometrial cancer risk.

Authors:  Monica McGrath; I-Min Lee; Julie Buring; Immaculata De Vivo
Journal:  Gynecol Oncol       Date:  2011-02       Impact factor: 5.482

2.  Endometrial Cancer Insulin-Like Growth Factor 1 Receptor (IGF1R) Expression Increases with Body Mass Index and Is Associated with Pathologic Extent and Prognosis.

Authors:  Amy S Joehlin-Price; Julie A Stephens; Jianying Zhang; Floor J Backes; David E Cohn; Adrian A Suarez
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-12-18       Impact factor: 4.254

3.  Polycystic Ovary Syndrome and the Forgotten Uterus.

Authors:  Pardis Hosseinzadeh; Maya Barsky; William E Gibbons; Chellakkan S Blesson
Journal:  F S Rev       Date:  2020-12-13

Review 4.  Metformin Use Is Associated with Reduced Incidence and Improved Survival of Endometrial Cancer: A Meta-Analysis.

Authors:  Yun-Liang Tang; Ling-Yan Zhu; Yu Li; Jiao Yu; Jiao Wang; Xiang-Xia Zeng; Kai-Xiang Hu; Jian-Ying Liu; Ji-Xiong Xu
Journal:  Biomed Res Int       Date:  2017-03-20       Impact factor: 3.411

5.  Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study.

Authors:  K Lindemann; L J Vatten; M Ellstrøm-Engh; A Eskild
Journal:  Br J Cancer       Date:  2008-03-25       Impact factor: 7.640

6.  Regulation of insulin-like growth factor signaling by metformin in endometrial cancer cells.

Authors:  Ya Xie; Jing-Lu Wang; Mei Ji; Zhong-Fu Yuan; Zheng Peng; Yi Zhang; Jian-Guo Wen; Hui-Rong Shi
Journal:  Oncol Lett       Date:  2014-08-20       Impact factor: 2.967

7.  Does Metformin affect ER, PR, IGF-1R, β-catenin and PAX-2 expression in women with diabetes mellitus and endometrial cancer?

Authors:  Anna Markowska; Monika Pawałowska; Violetta Filas; Konstanty Korski; Marian Gryboś; Stefan Sajdak; Anita Olejek; Wiesława Bednarek; Beata Spiewankiewicz; Jolanta Lubin; Janina Markowska
Journal:  Diabetol Metab Syndr       Date:  2013-12-05       Impact factor: 3.320

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.